Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.

Haché G, Shindo K, Albin JS, Harris RS.

Curr Biol. 2008 Jun 3;18(11):819-24. doi: 10.1016/j.cub.2008.04.073. Epub 2008 May 22.

2.

Vif and Apobec3G in the innate immune response to HIV: a tale of two proteins.

Farrow MA, Sheehy AM.

Future Microbiol. 2008 Apr;3(2):145-54. doi: 10.2217/17460913.3.2.145. Review.

PMID:
18366335
3.

[Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].

Fan B, Cen S, Jiang JD.

Yao Xue Xue Bao. 2008 Jul;43(7):678-82. Review. Chinese.

PMID:
18819469
4.

[Recent advances in the study of mechanism of APOBEC3G against virus].

Zhu YP, Jiang JD, Peng ZG.

Yao Xue Xue Bao. 2014 Jan;49(1):30-6. Review. Chinese.

PMID:
24783502
5.

The viral infectivity factor (Vif) of HIV-1 unveiled.

Rose KM, Marin M, Kozak SL, Kabat D.

Trends Mol Med. 2004 Jun;10(6):291-7. Review.

PMID:
15177194
6.

[Progress in the study of HIV-1 Vif and related inhibitors].

Li ZY, Zhan P, Liu XY.

Yao Xue Xue Bao. 2010 Jun;45(6):684-93. Review. Chinese.

PMID:
20939174
7.

HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.

Kremer M, Schnierle BS.

Curr HIV Res. 2005 Oct;3(4):339-44. Review.

PMID:
16250885
8.

APOBEC proteins and intrinsic resistance to HIV-1 infection.

Malim MH.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):675-87. doi: 10.1098/rstb.2008.0185. Review.

9.

New insights into the role of Vif in HIV-1 replication.

Schröfelbauer B, Yu Q, Landau NR.

AIDS Rev. 2004 Jan-Mar;6(1):34-9. Review.

PMID:
15168739
10.

[Research methods of anti-HIV-1 inhibitors targeting at Vif-APOBEC3G axis].

Qiao X, Zhang W, Li Z, Zeng Y.

Zhongguo Zhong Yao Za Zhi. 2011 Mar;36(6):806-9. Review. Chinese.

PMID:
21710755
11.

Recent insights into HIV-1 Vif.

Navarro F, Landau NR.

Curr Opin Immunol. 2004 Aug;16(4):477-82. Review.

PMID:
15245742
12.

HIV-1 Vif, APOBEC, and intrinsic immunity.

Goila-Gaur R, Strebel K.

Retrovirology. 2008 Jun 24;5:51. doi: 10.1186/1742-4690-5-51. Review.

13.

Cellular interactions of virion infectivity factor (Vif) as potential therapeutic targets: APOBEC3G and more?

Carr JM, Davis AJ, Feng F, Burrell CJ, Li P.

Curr Drug Targets. 2006 Dec;7(12):1583-93. Review.

PMID:
17168833
14.

Apobec3G-Based Strategies to Defeat HIV Infection.

Ran X, Ao Z, Yao X.

Curr HIV Res. 2016;14(3):217-24. Review.

PMID:
26957196
15.

Death by deamination: a novel host restriction system for HIV-1.

Goff SP.

Cell. 2003 Aug 8;114(3):281-3. Review.

16.

HIV accessory proteins versus host restriction factors.

Strebel K.

Curr Opin Virol. 2013 Dec;3(6):692-9. doi: 10.1016/j.coviro.2013.08.004. Epub 2013 Nov 15. Review.

17.

Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha.

Huthoff H, Towers GJ.

Trends Microbiol. 2008 Dec;16(12):612-9. doi: 10.1016/j.tim.2008.08.013. Epub 2008 Oct 29. Review.

18.

Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.

Münk C, Jensen BE, Zielonka J, Häussinger D, Kamp C.

Viruses. 2012 Nov 14;4(11):3132-61. doi: 10.3390/v4113132. Review.

19.

The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.

Chiu YL, Greene WC.

Annu Rev Immunol. 2008;26:317-53. doi: 10.1146/annurev.immunol.26.021607.090350. Review.

PMID:
18304004
20.

Suppression of APOBEC3-mediated restriction of HIV-1 by Vif.

Feng Y, Baig TT, Love RP, Chelico L.

Front Microbiol. 2014 Aug 26;5:450. doi: 10.3389/fmicb.2014.00450. eCollection 2014. Review.

Supplemental Content

Support Center